How could the stalled drug approval process affect Rachel Reeves?
Political pressure over high-cost drug access may challenge NHS funding priorities. The stalled discussions between Biogen and the National Institute for Health and Social Care (NICE) regarding omaveloxolone mean the life-changing drug cannot be recommended for NHS use, despite its potential to slow Friedrich's ataxia. This situation, amplified by a petition attracting 100,000 signatures, places significant political pressure on the Department of Health and Social Care.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- Still developing
How it reaches Rachel Reeves
-
Discussions between Biogen and the National Institute for Health and Social Care (NICE) regarding the inclusion of the drug omaveloxolone (Skyclarys) on the National Health Service (NHS) have stalled. The drug, which treats Friedrich's ataxia, is approved for private use in the UK but costs approximately £1,000 a day. Frank Bruno signed a petition delivered to the Prime Minister, prompting Labour MP David Burton-Sampson to push for accelerated policy talks.
The full event1independent outlet -
The high cost of the medication, which is about £1,000 a day, combined with the public and political outcry over its unavailability, increases the scrutiny on the government's ability to fund necessary, high-cost treatments. As Chancellor of the Exchequer, Rachel Reeves is responsible for the overall fiscal management and budget allocation of the government, making this a direct financial and political challenge.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
British politician and current Chancellor of the Exchequer (born 1979)
Everything about Rachel Reeves
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The drug, omaveloxolone, costs about £1,000 a day.bbc.co.uk
- Discussions between Biogen and the National Institute for Health and Social Care (NICE) to get it on the NHS have stalled.bbc.co.uk
- The petition on the matter attracted 100,000 signatures.bbc.co.uk
- Friedrich's ataxia is a progressive neurodegenerative disease that affects about 1,100 people in the UK.bbc.co.uk
Why it matters
The availability of life-changing, high-cost drugs like omaveloxolone represents a major tension point in the UK's healthcare system. For patients like Brogan Johnson, the denial of access is a tragic situation, but for the government, it represents a significant financial and ethical challenge regarding how public funds are allocated to rare and expensive treatments.
This issue is part of a broader, ongoing debate about the sustainability of the National Health Service (NHS) and the role of regulatory bodies like NICE. The political pressure generated by such cases forces the government to balance the need for cutting-edge medical care against the constraints of the national budget.
What we don't know yet
- Will the Department of Health and Social Care find a way to resume the drug approval process?
- How will the government respond to the political pressure regarding the cost of omaveloxolone?
What would change this answer
— Other considerations
Beyond this explainer
Explore connected ideas
Each opens in Related concepts: what the web connects to it, with Brind's news on it.
The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.
Who else could feel it
Other possible ripples from the same event.
Reporting
- bbc.co.ukYesterday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.